Last checked at 3 Jan 2023 07:02
ReNeuron Group plc
("ReNeuron", the "Group" or the "Company")
Total Voting Rights
At 31 December 2022, the Company had 57,173,760 Ordinary Shares in issue, each carrying one voting right.
As the Company holds no ordinary shares in treasury, the figure of 57,173,760 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
Contacts:
ReNeuron | www.reneuron.com/investors | |
Iain Ross, Executive Chairman | Via Walbrook PR | |
John Hawkins, Chief Financial Officer | ||
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) | +44 (0)20 3110 2000
| |
Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 | |
James Reeve/George Payne (Corporate Finance) | ||
Stefano Aquilino (Sales & Corporate Broking) | ||
Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com | |
Paul McManus / Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Group has out-licensed its CTX programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com